BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash growth accelerates
Q1 FY2026 net change in cash of $321.03M (cash outflow) rose 43598.7% year over year, ahead of the +6607.5% change in trailing-twelve-month net change in cash. Sequentially, it rose 815.8% from the prior quarter.
Context
- Net change in cash increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +43598.7% holds above the trailing-twelve-month pace of +6607.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 342.84M USD
- Year-over-year change
- +20093.2%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 342.84M | +20093.2% |
| FY2024 | 2024-12-31 | 1.7M | +654.6% |
| FY2023 | 2023-12-31 | 225K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Change in Cash vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6607.5% is the highest of 10, against a peer median of +111.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $641.62M USD | +3223.9% | — | 91.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $152.87M USD | -166.0% | — | 158.8% |
| LTM Mar 2026 | $149.83M USD | +233.4% | — | 64.5% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $57.3M USD | +6607.5% | — | — |
| LTM Mar 2026 | $31.41M USD | -71.4% | +81.7% | 15.3% | |
| LTM Sep 2026 | $28.07M USD | +440.8% | — | — | |
| LTM Sep 2026 | $14.4M USD | +111.4% | — | — | |
| LTM Mar 2026 | $6.19M USD | +122.8% | — | 4.4% | |
| LTM Mar 2026 | CHF 3.82M CHF | -89.2% | — | 758.5% | |
| LTM Jun 2026 | $126K USD | -99.1% | — | 0.1% | |
| Peer median (excluding BBOT) | — | +111.4% | +81.7% | 64.5% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (74) | (3.52K) | (41.69K) | 7.6M | (134.04M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Change in Working Capital | 0 | 0 | 15K | (104.61K) | 6.43M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 172.52K | (1.84M) |
| Other Working Capital | 0 | 0 | 15K | (277.13K) | 8.27M |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | (8.53M) | 7.23M |
| Operating Cash Flow | 0 | 0 | (52.08M) | (763.82K) | (113.89M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (606K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (184M) | (83.93M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 157.86M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (184M) | 73.33M |
| Debt Repayment | 0 | 0 | 0 | (209.85K) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 187.25M | 395.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (578.55K) | (12.32M) |
| Financing Cash Flow | 0 | 0 | 0 | 186.46M | 383.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 225K | 1.7M | 342.84M |
| Free Cash Flow | 0 | 0 | (52.49M) | (763.82K) | (114.5M) |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.